Company news: CVS, LiveStrong

Share this article:
CVS is getting serious about generics, and has knocked off a few brand names from its PBM formulary for 2013, reported the Wall Street Journal. The Journal noted that the drugstore chain started eliminating high-cost prescriptions over the summer. Some of these have made their way back onto the formulary, including Lilly/BI's Tradjenta, but the drug store chain is striking Allergan's glaucoma medicine Lumigan, Pfizer's human growth hormone Genotropin and the BMS/AstraZeneca diabetes med Onglyza, reported the WSJ.

Shifting gears faster than some expected, the Livestrong Foundation and Lance Armstrong have parted ways, reported the New York Times. The disgraced cyclist and cancer survivor founded the Livestrong foundation in 1997. Although he resigned as chair, following the United States Anti-Doping Agency's conclusion that Armstrong was guilty of doping while competing for the Tour de France, he was still a member of the board until November 4, reported the Times. He was stripped of his Tour titles and banned from future Olympics sports. Jeff Garvey has replaced him as chairman.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.